Bio Screening Industry News

Archive for the 'News by Region' Category

November 11, 2009

Weighing & Pipetting Skills and Solutions

Filed under: North America, USA and Canada — admin @ 3:39 pm

FREE Weighing & Pipetting Skills and Solutions Seminar on Thursday, December 3, 2009 at the Doubletree Hotel & Executive Meeting Center in Somerset, NJ.

In these challenging times where training budgets are stretched and laboratories are searching for new efficiencies to improve productivity, METTLER TOLEDO can help. This half-day Insight! Education seminar will focus on the METTLER TOLEDO Good Weighing Practice™ (GWP®) program and Pipetting 360° from RAININ, and will include an introduction to associated solutions for the laboratory. The seminar is valued at $495.00 per person, but is completely free of charge with your advance registration - however, space is limited, so register today!

Learn from Acknowledged Industry Authorities:

Proper weighing and pipetting skills and operations are fundamental laboratory functions critical to achieving accurate results in your analytical processes. Yet, there is often confusion on many aspects with regards to balance and pipette use and operation.

Instructor - Henry Oppermann, former Division Chief for Weights and Measures, National Instituted of Standards [NIST].

Learn the Good Weighing Practice (GWP®) approach to selection, use, calibration, and ongoing management of balances for your laboratory, department, or even entire organization from an acknowledged industry authority. During his career, Henry Oppermann has been instrumental in developing many of the guidelines and practices designed to improve weighing processes. Join him and experts from METTLER TOLEDO for this insightful session.

Together with knowledgeable experts on the RAININ 360° approach to pipette use and management, you’ll learn valuable risk-based approaches to working with two of the most common - yet critical instruments in the lab, that will enhance your skills, career and results in any industry setting!

Also, we’re pleased to introduce Quantos - a revolutionary innovation for routine and precise dosing of powder compounds in the lab. Quantos is the winner of the 2009 Lab Automation Association and R&D 100 Awards! Learn more about how Quantos can improve speed, safety, and savings in your lab. See Quantos and a variety of other METTLER TOLEDO solutions live following the seminar during our product exposition.

If you think a colleague would be interested in attending this informative seminar, then forward to a colleague.

Date:    Thursday, December 3, 2009
Time:    8:30 am - 12:15 pm (Continental Breakfast at 8:00am / Lunch following seminar.)
Cost:    FREE with Advance Registration. Hurry - Space is limited! Free parking.
Location:    Doubletree Hotel & Executive Meeting Center 200 Atrium Drive, Somerset, New Jersey 08873

Schedule

Time:
8:00am – 8:30am Arrival & Check-in with Complimentary Continental Breakfast
8:30am – 12:15pm Seminar and speakers
12:15pm – 1:30pm Complimentary lunch concurrent with product exposition
Free parking.

Cost:
FREE with Registration (A $495 Insight! Education value)

Agenda:

8:00 am – 8:30 am: Check-in and Complimentary Continental Breakfast

8:30 am to 10:15 am – Good Weighing Practice™ GWP® Presented by Henry Oppermann, Former Division Chief for Weights and Measures at the National Institutes of Standards and Technology (NIST).

Minimize weighing risks with a minimum of effort. Good Weighing Practice allows you to improve control of your whole measuring process from balance Evaluation, Selection, Installation, Calibration and Routine Operation. With Good Weighing Practice you weigh without risks, comply with regulations easily, and achieve consistent good quality of your product and analytical processes appropriate for your industry or application.  Click here to learn more about Good Weighing Practice.

10:15 am to 10:30 am – Break

10:30 am to 10:55 am - Minimizing Weighing Measurement Uncertainty
METTLER TOLEDO knows it is essential for you to produce accurate results, achieve compliance, and improve traceability in the lab. See how to address all requirements regarding measurement uncertainty as outlined in ISO 17025 and ISO 9000/9001. Ensure strict compliance with your Quality Management SOP’s. Verify all calibrations and automatically perform routine weight checks on schedule while efficiently capturing your weighing data transparently while meeting all regulatory requirements.

10:55 am to 11:20 am – A New Solution in Automated Powder Dosing
New QUANTOS™ from METTLER TOLEDO solves many of the challenges of repetitive weighing of powder materials, such as reference standards for use with chromatography and other analytical lab applications, capsule filling or inhaler work, bottling, and more. Precise dosing of small amounts of powder in the Bio/Pharmaceutical or the chemical laboratory is a difficult, time consuming, and potentially hazardous task. Often the scientist is in contact with highly potent compounds or has a limited amount of precious material, and dosing may be hindered by electrostatic or hygroscopic effects. QUANTOS solves these challenges and more. Click here to learn more about QUANTOS™.

11:20 am to 12:15 pm – Good Practices in Pipette Use and Management - Pipetting 360°
Pipette liquid handling involves a variety of principles and practical considerations. This informative presentation from RAININ will cover handling principles with practical considerations, address how to best maximize accuracy & performance technique in your pipette work, tip selection and application, calibration approaches and solutions, and steps you can take to improve your results and productivity. Click here to learn more about RAININ Pipettes.

12:15 pm – 1:30 pm – Complimentary Lunch and Product Exposition
A Free Product Exposition will run concurrent with and following a noon luncheon where you can see a variety of these and other METTLER TOLEDO and RAININ Solutions displayed and demonstrated, while having your questions answered.

Exposition Products and Technologies will include:

* Analytical, Precision, and MicroBalances from METTLER TOLEDO
* QUANTOS® Perfect Dosing Solution
* RAININ Pipette Solutions including the New Rainin Liquidator 96 Benchtop Pipetting System
* Pipette Calibration Workstations
* Potentiometric and Karl Fischer Titrators from METTLER TOLEDO
* Density & Refractometry Systems
* pH measurement solutions
* Thermal Analysis including DSC, TGA, TMA, and DMA technologies and melting point solutions
* Moisture Balances
* LabX Software for Balance and Instrument control and data capture.
* And more…

1:30 pm – Conclude

Doubletree Hotel & Executive Meeting Center
200 Atrium Drive
Somerset, New Jersey 08873

http://mt.com/us/en/home/events/fairs/somerset_semin.html

Biochrom’s new Anthos Instant Microplate Solution (AIMS)

Filed under: Europe, New Products — admin @ 3:26 pm

If you have a new project a new job or a new lab you can stretch your budget further with Biochrom’s new Anthos Instant Microplate Solution (AIMS). This package has all the microplate instrumentation you need at a great price.

AIMS is ideal for laboratories that handle a large number of ELISA or other absorbance based assays and that need the flexibility for future applications.

“Top of the range” Anthos microplate instrumentation and software:

* Zenyth 200 monochromator Microplate Reader with built-in cuvette UV/Vis spectrophotometer.
* Fluido 2 four channel microplate washer.
* Free PC analysis software.
* Free laser printer.

Anthos instruments are CE marked and made under our rigorous quality system. Building on Anthos’s 25 years experience in microplate instrumentation, AIMS represents new thinking for the next generation providing total flexibility for microplate absorbance applications. Get more from your budget with Biochrom.
Find out more see www.biochrom.co.uk/aims

October 10, 2009

Zelinsky Institute Inc. announced collaboration with ART-CHEM

Zelinsky Institute Inc. (Newark, DE, August 2009) - Zelinsky Institute Inc. expands its partnership and supplier network with the announcement of collaboration with one of the premier fine chemistry companies - ART-CHEM, which originated from Moscow, Russia, and has started its operations in Berlin, Germany, in 2005. ART-CHEM specializes in synthesis of highly diverse and rich in unique scaffolds HTS compounds and building blocks. The entire line of ART-CHEM product offerings is going to be available via Zelinsky Institute Inc., which is headquartered in and currently operates from Delaware, USA, offices.

ART-CHEM founder, Dr. B. Ugrak, comments, “We are pleased to become a part of Zelinsky Institute, a recognized supplier of specialty chemicals. Together we can provide greater value serving our, now, joined customer base.” Zelinsky Institute CEO, Dr. M. Niazoff, agrees adding, “We are happy to have ART-CHEM high quality fine chemistry products and service capabilities accessible via Zelinsky Institute. Together, we are looking forward to growing our market fueled by ever-evolving research demands.”

Collaboration aims at making ART-CHEM products and services known and easily accessible for existing and prospective Zelinsky Institute Inc. customers worldwide. September 2009 product databases distributed by Zelinsky Institute Inc. are going to include ART-CHEM’s drug-like and chemically diverse compounds for screening, building blocks, and intermediates. Zelinsky Institute Inc. is going to coordinate procurement, orders, and consolidated delivery of HTS products. Zelinsky Institute Inc. and ART-CHEM collaboration is open to custom projects going beyond the supply of just existing fine organic chemistry. For recently launched databases, products and services, inquiries, orders, and customized solutions please contact

August 21, 2009

Sirona Biochem Optimizes Key Test for Diabetes and Obesity Drug Development

VANCOUVER, BC — (Marketwire) — 07/16/09 — Sirona Biochem Corp. (TSX-V: SBM) announced today it is now ready to begin testing its novel new compounds to fight diabetes and obesity.

The completion of the company’s key SGLT biological assessment test and testing will be done under contract with Richmond, BC based SignalChem.

Sirona Biochem owns the worldwide rights to a library of potential new sodium glucose transporter (SGLT) inhibitors developed to treat diabetes and obesity. SGLT Inhibitors are a novel new drug class currently under development that block the reuptake of excess sugars from urine in the kidney which can then reduce high blood sugar to normal levels. Excess sugar in the blood is a primary medical challenge associated with treating diabetes and obesity.

Sirona has a research and development agreement with TFChem (Rouen, France), where a significant number of SGLT drug analogs are being prepared for first stage evaluation. Preliminary primary stage testing conducted earlier this year provided positive indications to support Sirona Biochem’s project and provided key insights to optimize the new test that is now ready for use to evaluate the next library set of molecules.

Mark Senner, President, explained, “SGLT inhibitors are a new and exciting class of compounds that have great promise to treat both diabetes and obesity which are now at epidemic levels worldwide. This new drug class is one considered to have extraordinary market potential in the fight against diabetes and obesity.

“Development of this new drug class however is challenging due to the fragile nature of these ’sugar’ based molecules that render them unstable and difficult to develop for clinical use. Given this challenge, it is believed that the use of the patented GlycoMim® technology, licensed from TFChem to develop SGLT Inhibitors, will increase drug stability and, therefore, improve their overall clinical effectiveness. Potential licensing and development partners have expressed interest in our concept of improving molecules in this new drug class. We intend to develop ‘best in class’ SGLT Inhibitors through use of this technology.

“The key and critical first test has been developed and optimized for use by SignalChem under contract from Sirona Biochem. Through use of this proprietary test, the company will be able to determine which molecules have the desired potency and selectivity compared to a reference standard. Screening of the current library of compounds will generate key data for ongoing drug development and provide first stage proof of concept necessary to secure future partnering opportunities. Sirona’s scientific team aims to identify lead compounds by the end of 2009,” continued Senner.

“The results from our new optimized test will be critical to direct our ongoing development of novel new SGLT inhibitors. The development and optimization of this sophisticated test, completed by SignalChem, is a significant and key milestone achievement for us. We are very pleased with the progress that we are making on our SGLT drug development program,” commented Senner.

Upon selection of compounds with the desired potency and selectivity for the SGLT 2 carrier protein, further preclinical screening for cytotoxicity, ADME properties, pharmacokinetics and in vivo efficacy will need to be carried out to select compounds for future clinical development. The primary objective of this critical first stage development plan with SignalChem was to develop, qualify and optimize the key test required for the initial development of SGLT inhibitors.

Investors are invited to visit the Sirona Biochem website at: http://www.sironabiochem.com where we feature the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to info@sironabiochem.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466.

About the Company:

Sirona Biochem Corp. (TSX-V: SBM) is a emerging biotech company dedicated to the discovery and development of novel drug compounds. The current focus is on treatments for Type II Diabetes and Obesity. Sirona has entered into a license agreement with TFChem S.A.R.L., a Drug Discovery company based in Rouen, France. TFChem licenses its technology of fluorinated carbohydrate mimics: GlycoMim®, and products in development to biotech companies. The license agreement with TFChem provides for research and development of new compounds known as S.G.L.T. inhibitors. S.G.L.T. inhibitors are a new and exciting class of compounds that have great promise and potential to treat both diabetes and obesity.

About SignalChem:

SignalChem, based in Richmond, B.C., Canada is a biotechnology company focused on the research, development and production of innovative cell signaling products to advance basic research and drug discovery efforts, with specific emphasis on the production of highly purified biologically active human recombinant proteins. SignalChem is emerging as a leader and a key contender in the life science recombinant protein market place. SignalChem offers a comprehensive discovery service which includes: gene cloning & expression of therapeutic ‘targets,’ custom assay & antibody development and compound profiling for drug ‘potency’ & ’selectivity.’

Mark Senner
President and Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Sirona Biochem
950-789 West Pender Street
Vancouver, B.C., V6C 1H2
Direct: 604-641-4466
Fax: 604-608-5471
info@sironabiochem.com

Source: www.sys-con.com

Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimer’s Disease

Start-up company continues momentum with selection of disease-modifying small molecule drug leads for behavioral testing
PITTSBURGH, July 16 /PRNewswire/ — Cognition Therapeutics Inc., a Pittsburgh-based drug discovery company developing small molecule disease-modifying treatments for Alzheimer’s, has closed on a $1.21M Series A financing. The round was led by Ogden CAP, LLC of New York City and includes M5Invest Partners of Villanova, PA, the Pittsburgh Life Sciences Greenhouse, Innovation Works (Pittsburgh), and several individual investors. The round included both new investments and the conversion of existing convertible notes.

“This investment facilitates the advancement of our existing lead molecules towards a major milestone,” said Cognition Therapeutics President and CEO Hank Safferstein, Ph.D., J.D. “Our combination of novel, small molecule drug candidates and biologically-relevant screening methods is unique in the pharmaceutical industry. We’re pleased to have Ogden CAP and M5Invest join our other investors in supporting our pioneering approach to treat or prevent Alzheimer’s disease by targeting the proteins that cause the earliest stages of this disease”.

“As early investors, we are impressed by Cognition Therapeutics’ combination of cutting-edge technology, influential and experienced leadership, and large clinical and commercial potential,” said Robert Gailus, senior advisor to Ogden CAP. “Alzheimer’s disease is a major health epidemic that places increasing strains on the world’s healthcare systems as the population ages. The drug candidates being developed by Cognition have the potential to significantly impact this devastating disease,” Gailus continued. Alzheimer’s disease affects an estimated four and a half million people in the United States today. That number is expected to exceed 12 million people by 2050.

Funds raised in this round will support advancement of Cognition Therapeutics’ pioneering lead molecules that block the activity of the toxic oligomeric form of Abeta protein that interferes with normal learning and memory. Studies from the world’s leading academic laboratories indicate that the memory deficits caused by the oligomeric protein are among the earliest changes seen in Alzheimer’s disease and Mild Cognitive Impairment, the precursor to Alzheimer’s. These studies indicate that blocking the effects of this protein may halt or reverse Alzheimer’s disease. Cognition will use these funds to test its most promising lead molecules in behavioral models of Alzheimer’s disease. “The advancement of the company’s lead compounds into behavioral testing represents a significant milestone for the company,” says Dr. Franz Hefti, Chairman of the Board. “Cognition’s scientific approach is unique among the approaches being taken by the pharmaceutical industry today. Cognition has a novel Alzheimer’s disease model for the critical molecular step that causes memory loss. In addition, the company’s proprietary chemistry is based on natural molecular scaffolds which brought us effective drugs like aspirin, lidocaine and taxol. We anticipate new disease-modifying drugs for Alzheimer’s disease will result from this unique combination,” Dr. Hefti continued.

About Cognition

Cognition Therapeutics, Inc. is a leader in the discovery and development of small molecule therapeutics targeting the toxic proteins that cause the cognitive decline associated with Alzheimer’s disease and other degenerative diseases of the human brain. Toxic proteins play a crucial role in a large class of diseases, and there are currently no therapeutics available to prevent or block the destructive effects of toxic oligomeric proteins. Cognition has leveraged its scientific expertise with these difficult targets to pioneer the use of proprietary assays that emphasize functional responses and proprietary medicinal chemistry that ensures novel, high quality small-molecule drug candidates for the treatment of these diseases.

Cognition has developed a number of screening strategies to identify small molecules capable of blocking the central toxicity of proteins in Alzheimer’s disease and other neurodegenerative diseases. These assays emphasize phenotypic or functional responses of mature primary neurons to the toxic proteins. Cognition’s proprietary chemistry platform converts natural products into low molecular weight chemically stable druglike molecules, and is thus a source of novel pharmacophores and valuable drug candidates. These two technology platforms harken back to the origins of the pharmaceutical industry, when phenotypic responses were the sole screening method and natural product derivatives formed the starting materials for successful drug discovery.

Cognition Therapeutics was founded on small molecule chemical libraries licensed from co-founder Dr. Gilbert Rishton at California State University Channel Islands and proprietary screening strategies established by co-founder and Chief Science Officer Dr. Susan Catalano. After initial investment and relocation to Pittsburgh, the company secured Dr. Hank Safferstein as President and CEO, bringing with him more than 15 years of leadership experience in drug development, commercialization and marketing for a number of public and private companies. www.cogrx.com.

About Ogden CAP, LLC

Ogden CAP, LLC is a New York company that has investments is a wide variety of asset classes, including venture capital. Over the past two years Ogden CAP, LLC has invested in 10 early stage companies. Besides its investment in Cognition, Ogden CAP, LLC has two other investments in the Pittsburgh area: FASTTAC, a document control and management company for the construction industry, and TSG, Inc. an energy company that converts coal to fuels.

About the Pittsburgh Life Sciences Greenhouse (PLSG)

The Pittsburgh Life Sciences Greenhouse (PLSG) provides capital investments and customized company formation and business growth services to western Pennsylvania’s life sciences enterprises. The PLSG supports biosciences companies with promising innovations in the following concentrations: Biotechnology Tools, Diagnostics, Healthcare IT, Medical Devices and Therapeutics. The PLSG is propelling the sustainable growth of the region’s life sciences economy by accelerating research and technology commercialization with seed and early-stage companies; connecting investors with their Investment Portfolio companies; expanding established life sciences ventures and relocating biomedical companies to Pennsylvania.

www.plsg.com

About Innovation Works (IW)

Innovation Works provides risk capital and business expertise to the most promising early-stage technology companies in Southwestern PA to help them grow and succeed. Innovation Works is one of the most active seed-stage investors in the country, having invested in more than 120 emerging technology companies since beginning their seed fund in 1999. Those companies have gone on to raise over $600 million in additional capital from a diverse set of VCs, private investors, strategic partners and other sources of capital.

SOURCE Cognition Therapeutics Inc.

Horizon Discovery signs screening agreement with SuperGen Inc.

Horizon Discovery today announced it has signed a commercial agreement with US Pharmaceutical company SuperGen, Inc., relating to its X-MAN technology.

Horizon’s X-MAN (Mutant And Normal) cell-line technology provides the first genetically-defined and patient-relevant in vitro models of human cancer. These models are being used by a growing number of Pharma and Biotech companies to rationalize key steps of the ‘targeted’ drug development process, and thus accelerate and economize the burgeoning field of ‘personalised’ medicine.

The agreement covers the screening of a number of lead compounds on a wide panel of human isogenic cell-lines comprising target genotypes of interest to SuperGen. The approach may enable SuperGen to gather information relating to the selectivity and mode-of-action of their compounds using model in-vitro systems.

“Dr Darrin M Disley, Commercial Director and Chairman of Horizon says “working with SuperGen is an exciting development for Horizon. In this expandable agreement, we hope to further prove the potential of our human X-MAN models in a screening environment; thus facilitating a long and productive relationship with SuperGen.”

SuperGen will pay Horizon undisclosed fees during the term of the agreement. Work between the parties will begin in July 2009.

About Horizon Discovery

Horizon Discovery is a translational genomics company founded in June 2007 and is headquartered at the Babraham Research Campus, Cambridge, UK and with additional research laboratories in Torino, Italy. Horizon’s goal is to convert new information on the genetic causes of cancer into laboratory models that will facilitate the discovery of drugs that target these defects. Central to this aim is Horizon Discovery’s offering of X-MAN cell-lines, which represent accurate models of defined cancer patient populations and their matched normal genetic backgrounds – a missing link in the rational and efficient development of novel targeted anti-cancer agents.

Source: Cambridge Network

The Further In You Go, The Bigger It Gets

Filed under: North America, Research Projects, Industry News, Compound Screening — Editor @ 1:02 pm

I had a printout of the structure of maitotoxin on my desk the other day, mostly as a joke to alarm anyone who came into my office. “Yep, here’s the best hit from the latest screen. . .I hear that you’re on the list to run the chemistry end. . .what’s that you say?”
Maitotoxin.jpg
This is, needless to say, one of the largest and scariest marine natural product structures ever determined (and that determination has been no stroll past the dessert table, either).

But that’ hasn’t stopped people from messing around with it. And there’s much speculation that other people are strongly considering messing around with it, too - you synthetic chemists can guess the sorts of people that this might be, and their names, and what it might be like to sit through the seminars that result, and so on.

I fear that a total synthesis of maitotoxin would be largely a waste of time, but I’m willing to hear arguments against that position. Just looking at it, though, inspires thought. This eldrich beastie has 98 chiral centers. So let’s do some math. If you’re interested in the SAR of such molecules, you have your choice of (two to the 98th) possible isomers, which comes out to a bit over (3 times ten to the 29th) compounds. This is. . .a pretty large number. If you’re looking for 10mg of each isomer to add to your screening collection (no sense in going back and making them again), then you’re looking at a good bit over half the mass of the entire Earth. And that’s just in sheer compounds; we’re not counting the weight of vials, which will, I’d say, safely move you up toward the planetary weight of a low-end gas giant. We will ignore shelving considerations in the interest of time.

Recall that yesterday’s post gave a number of about 27 million compounds below 11 heavy atoms. You could toss 27 million compounds into a collection of ten to the 29th and never see them again, of course. But that brings up two points: one, that the small-compound estimate ignores stereochemistry, and we’ve been getting those insane maitotoxin numbers by considering nothing but. The thing is, with only 11 non-hydrogen atoms, there aren’t quite as many chances for things to get out of control. The GDB compound set goes up only to 110 million or so if you consider stereoisomers, which actually isn’t nearly as much as I’d thought.

But the second point is that this shows you why the Berne group stopped at 11 heavy atoms, because the problem becomes intractable really fast as you go higher. It’s worth remembering that the GDB people actually threw out over 98% of their scaffolds because they represented potential ring structures that are too strained to be very stable. And they only considered C, N, O and F as heavy atoms (even adding sulfur was considered too much to deal with, computationally). Then they tossed out another 98 or 99% of the structures that emerged from that enumeration as reactive and/or unstable. Relax your standards a bit, allow another atom or two, bump up the molecular weight, do any of those and you’re going to exceed anyone’s computational capacity. Update: the Berne group has just taken a crack at it, and managed a reasonable set up to 13 heavy atoms, with various simplifying assumptions to ease the burden. If you want to mess around with it, it’s here, free of charge).

Source: Corante

May 27, 2009

International Swine Flu Conference August 19-21 Washington DC

Filed under: North America, USA and Canada, Press Releases, Swine Flu Research — admin @ 3:05 pm

Top leaders and key decision-makers of major companies representing a broad range of industries will meet with distinguished scientists, public health officials, law enforcers, first responders, and other experts to discuss pandemic prevention, preparedness, response and recovery at the 1st International Swine Flu Summit.

At the summit, attendees will be able to draw on first-hand best practices to create the solid business continuity plans that their companies and organizations need in order to prepare for, respond to, and survive a pandemic.

The summit draws on the success of the seven previous Bird Flu summits which featured as speakers several distinguished personalities such as Dr. David Nabarro, the United Nations Coordinator for Avian and Human Influenza, Alex Thiermann of the World Organization for Animal Health (OIE) and Dr. Wenqing Zhang of the WHO Epidemic and Pandemic Alert and Response.

Well-known emergency responders, heads of hospitals from around the world, and hog/swine industry leaders will speak in this summit.

Topics Include:
Country Report & Situations Update
Surveillance and Data Management
Preparing Communities Strategies; Local Partnership and Participation
Delivery of Vaccine and Antiviral Medication
National Pandemic Influenza Medical Countermeasure
Socio Economic Impact on Hog/Swine Industry
Benefit-risk Assessment: Public Health, Industry and Regulatory Perspectives
Prevention Education Efforts and Risk Communication
Command, Control and Management
Emergency Response Management
Business-Based Planning
School-Based Planning
Community-Based Planning

http://new-fields.com/isfc/

May 13, 2009

TimTec Expands Partnership With Collaborative Drug Discovery Through Publishing Three Additional Libraries on CDD’s Free Public Access Database

Last October, TimTec and Collaborative Drug Discovery (CDD) established a collaboration in which CDD’s web-based data management system would host two TimTec Natural Products libraries on their free community Public Access site.  Through this partnership, researchers would be able to register for a free account with CDD allowing them to chemically mine the contents of these TimTec compound libraries using CDD’s powerful, intuitive web-based database software.

TimTec is now offering three more libraries on the CDD Public Access database:

The TimTec ActiTarg-K Kinase Modulators library contains over 6,000 compounds known to inhibit protein kinase activity:

http://www.timtec.net/actitarg-k-kinase-modulators.html

The TimTec OGT Inhibitors Analogs library contains more than 300 compounds analogous to three known O-GlcNAc Transferase inhibiting molecules:

http://www.timtec.net/o-glcnac-transferase-inhibitors.html

Finally, the TimTec resourceful Diversity Set is a general screening collection of drug-like compounds that present most diversified selection from TimTec stock. This screening library contains 10,000 of the most diverse compounds, all complying with the Lipinski Rule of Five:

http://www.timtec.net/diversity-set-10k.html

TimTec’s five databases join more than 25 other databases containing chemical and biological data hosted on CDD Public Access, including:

  • 47,000 Ki values for 20,000 compounds against 699 GPCR targets from the NIMH Psychoactive Drug Screening Program at the University of North Carolina
  • Over 15,000 compounds with Malaria assay data from 5 public data sources
  • 48,818 compounds from the Distributed Drug Discovery (D3) at Indiana University – Purdue University Indianapolis (IUPUI)
  • Almost 7,500 compounds with Tuberculosis antibacterial and cell viability information from 4 public data sets and growing thanks to their collaboration with the Bill & Melinda Gates Foundation

About TimTec, LLC.

TimTec LLC. - http://www.timtec.net - is a privately held company located in NewarkDelaware, USA. It was founded in 1995 and began its work in the areas of acquisition and distribution of synthetic organic and natural compounds, custom synthesis, and laboratory equipment to become a full service partner for drug discovery. TimTec has established a global network of thousands of scientists from research centers around the world. The company has developed strong in-house expertise assembling general and targeted library collections for variety of research purposes. International customers include major pharmaceutical, biotech, agricultural, and educational companies and institutions, which use TimTec products for research and development programs.

For more information on TimTec library collections, please contact:

Kay Denisova
Business Development
TimTec LLC
Harmony Business Park Building 301-A
Newark, DE 19711
Tel 302 292 8500
Fax 302 292 8520
info(at)timtec.net
http://www.timtec.net

About Collaborative Drug Discovery, Inc.

Collaborative Drug Discovery, Inc. (CDD) - http://www.collaborativedrug.com - provides web-based software that organizes preclinical research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to “archive, mine, and collaborate”® around preclinical chemical and biological drug discovery data through a web-based interface. The software helps distributed research groups to safely store and intelligently analyze small molecule, enzyme, cell and animal bioactivity data accumulated from both low-throughput and high-throughput screens. Unique collaboration features and CDD’s community-oriented approach help unite globally dispersed humanitarian efforts against neglected infectious diseases. Similar collaborative strategies are also rapidly gaining prominence in the commercial arena. CDD offers its industrial-strength database software at a price affordable to academic laboratories, research foundations, and small companies.

For further information please contact:

Barry Bunin, PhD
President & CEO
Collaborative Drug Discovery (CDD)
1633 Bayshore Hwy, Suite 342
Burlingame, CA 94010
info(at)collaborativedrug.com

May 10, 2009

3rd International Symposium on Advances in Synthetic and Medicinal Chemistry

Kiev, Ukraine, August 23 - 27, 2009

ASMC09 in Kiev is being prepared by EFMC (European Federation for Medicinal Chemistry) and ChemBridge Corporation, in the series of events which started with ASCMC04 Moscow followed by ASMC07 St. Petersburg.

Prof. Erick Carreira, ETH Zurich, Switzerland and Dr Scott Biller, Novartis Institutes for BioMedical Research, Cambridge, USA, have kindly accepted to be the Chairmen of the Symposium.

The scientific program of the International Symposium on Advances in Synthetic and Medicinal Chemistry will include:

* 28 invited plenary lectures, presented by highly recognized scientists from academia and the pharmaceutical and biotech industry from Europe, USA and former USSR countries.
* 10 short oral communications which will be selected from submitted abstracts
* poster sessions

The scientific program will be complemented by an attractive cultural program in Kiev.

The topics to be covered during this symposium include:

* New Synthetic Methodologies, Total Synthesis of Natural Products and Heterocyclic Chemistry
* Diversity- and Target-Oriented Synthesis and Chemical Biology
* Medicinal Chemistry and Drug Discovery & Development

The program will also include a commercial exhibition and a half-day Business Mini-Symposium “Small Molecule Screening Libraries in Drug Discovery: Experience and Trends”.

The official language of the symposium is English.

http://www.ldorganisation.com

Next Page »

Powered by WordPress